Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

355 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine.
Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, Caulfield MJ, Irwin MR, Smith JG, Clair J, Chan IS, Williams H, Harbecke R, Marchese R, Straus SE, Gershon A, Weinberg A; Veterans Affairs Cooperative Studies Program Shingles Prevention Study Investigators. Levin MJ, et al. Among authors: caulfield mj. J Infect Dis. 2008 Mar 15;197(6):825-35. doi: 10.1086/528696. J Infect Dis. 2008. PMID: 18419349 Free PMC article. Clinical Trial.
Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine.
Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, Chan IS, Li DJ, Wang W, Keller PM, Shaw A, Silber JL, Schlienger K, Chalikonda I, Vessey SJ, Caulfield MJ. Levin MJ, et al. Among authors: caulfield mj. J Infect Dis. 2003 Nov 1;188(9):1336-44. doi: 10.1086/379048. Epub 2003 Oct 17. J Infect Dis. 2003. PMID: 14593591
Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine.
Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, Caulfield MJ, Irwin MR, Clair J, Smith JG, Stanley H, Marchese RD, Harbecke R, Williams HM, Chan IS, Arbeit RD, Gershon AA, Schödel F, Morrison VA, Kauffman CA, Straus SE, Schmader KE, Davis LE, Levin MJ; US Department of Veterans Affairs (VA) Cooperative Studies Program Shingles Prevention Study Investigators. Weinberg A, et al. Among authors: caulfield mj. J Infect Dis. 2009 Oct 1;200(7):1068-77. doi: 10.1086/605611. J Infect Dis. 2009. PMID: 19712037 Free PMC article. Clinical Trial.
Varicella zoster virus-specific immune responses to a herpes zoster vaccine in elderly recipients with major depression and the impact of antidepressant medications.
Irwin MR, Levin MJ, Laudenslager ML, Olmstead R, Lucko A, Lang N, Carrillo C, Stanley HA, Caulfield MJ, Weinberg A, Chan IS, Clair J, Smith JG, Marchese RD, Williams HM, Beck DJ, McCook PT, Zhang JH, Johnson G, Oxman MN. Irwin MR, et al. Among authors: caulfield mj. Clin Infect Dis. 2013 Apr;56(8):1085-93. doi: 10.1093/cid/cis1208. Epub 2013 Feb 13. Clin Infect Dis. 2013. PMID: 23413415 Free PMC article.
Major depressive disorder and immunity to varicella-zoster virus in the elderly.
Irwin MR, Levin MJ, Carrillo C, Olmstead R, Lucko A, Lang N, Caulfield MJ, Weinberg A, Chan IS, Clair J, Smith JG, Marchese RD, Williams HM, Beck DJ, McCook PT, Johnson G, Oxman MN. Irwin MR, et al. Among authors: caulfield mj. Brain Behav Immun. 2011 May;25(4):759-66. doi: 10.1016/j.bbi.2011.02.001. Epub 2011 Feb 15. Brain Behav Immun. 2011. PMID: 21329753 Free PMC article. Clinical Trial.
Measurement of cell-mediated immunity with a Varicella-Zoster Virus-specific interferon-gamma ELISPOT assay: responses in an elderly population receiving a booster immunization.
Smith JG, Levin M, Vessey R, Chan IS, Hayward AR, Liu X, Kaufhold RM, Clair J, Chalikonda I, Chan C, Bernard M, Wang WW, Keller P, Caulfield MJ. Smith JG, et al. Among authors: caulfield mj. J Med Virol. 2003;70 Suppl 1:S38-41. doi: 10.1002/jmv.10318. J Med Virol. 2003. PMID: 12627485
Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age.
Vermeulen JN, Lange JM, Tyring SK, Peters PH, Nunez M, Poland G, Levin MJ, Freeman C, Chalikonda I, Li J, Smith JG, Caulfield MJ, Stek JE, Chan IS, Vessey R, Schödel FP, Annunziato PW, Schlienger K, Silber JL. Vermeulen JN, et al. Among authors: caulfield mj. Vaccine. 2012 Jan 20;30(5):904-10. doi: 10.1016/j.vaccine.2011.11.096. Epub 2011 Dec 7. Vaccine. 2012. PMID: 22154769 Clinical Trial.
Safety, tolerability, and immunogenicity of a two-dose regimen of high-titer varicella vaccine in subjects > or =13 years of age.
Diaz C, Dentico P, Gonzalez R, Mendez RG, Cinquetti S, Barben JL, Harmon A, Chalikonda I, Smith JG, Stek JE, Robertson A, Caulfield MJ, Biasio LR, Silber JL, Chan CY, Vessey R, Sadoff J, Chan IS, Matthews H, Wang W, Schlienger K, Schödel FP; Protocol 049 Study Group. Diaz C, et al. Among authors: caulfield mj. Vaccine. 2006 Nov 17;24(47-48):6875-85. doi: 10.1016/j.vaccine.2006.06.030. Epub 2006 Jul 7. Vaccine. 2006. PMID: 17050042 Clinical Trial.
355 results